The estimated Net Worth of Christopher Galletta is at least $12.3 Tausend dollars as of 2 January 2012. Mr Galletta owns over 500 units of Trevi Therapeutics stock worth over $1,650 and over the last 14 years he sold TRVI stock worth over $10,676.
Mr has made over 3 trades of the Trevi Therapeutics stock since 2010, according to the Form 4 filled with the SEC. Most recently he exercised 500 units of TRVI stock worth $1,090 on 2 January 2012.
The largest trade he's ever made was exercising 1,600 units of Trevi Therapeutics stock on 12 November 2010 worth over $6,544. On average, Mr trades about 328 units every 46 days since 2010. As of 2 January 2012 he still owns at least 500 units of Trevi Therapeutics stock.
You can see the complete history of Mr Galletta stock trades at the bottom of the page.
Christopher Galletta is the Controller & Chief Accounting Officer at Trevi Therapeutics.
Mr Galletta is 43, he's been the Controller & Chief Accounting Officer of Trevi Therapeutics since . There are 19 older and no younger executives at Trevi Therapeutics. The oldest executive at Trevi Therapeutics, Inc. is Anne VanLent, 72, who is the Independent Director.
Christopher's mailing address filed with the SEC is C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, 16TH FLOOR, NEW HAVEN, CT, 06510.
Over the last 6 years, insiders at Trevi Therapeutics have traded over $2,844,492 worth of Trevi Therapeutics stock and bought 79,366,506 units worth $381,350,992 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Forest Baskett und Scott D Sandell. On average, Trevi Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $3,549,117. The most recent stock trade was executed by Jennifer L Good on 6 September 2024, trading 6,059 units of TRVI stock currently worth $8,664.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Trevi Therapeutics executives and other stock owners filed with the SEC include: